Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?

The IMforte trial specifically excluded these patients, a major drawback of this trial in my opinion. It may not be unreasonable to consider it, especially if the patient has a good performance status and is motivated to get it. However, I would discuss the pros and cons and make it clear that this ...